Recent news highlights include Q1 2026 earnings reporting a loss and revenue below expectations, detailed earnings call transcripts, and ongoing clinical development progress for MELT-300 and other pipeline assets.

• Harrow reported a net loss and revenue below expectations for Q1 2026, with detailed earnings call transcripts providing insights into operational performance [N2][N3][N4].
• The company is advancing MELT-300 toward FDA approval with ongoing non-clinical and pharmacokinetic studies supporting NDA submission preparations [S1].
• Harrow acquired the remaining equity interests of Melt Pharmaceuticals in November 2025, consolidating ownership of MELT-300 and related R&D activities [S1].
• Pricing and reimbursement pressures from government and commercial payors continue to affect profitability and patient access [S2].
• The company maintains strong liquidity with cash and equivalents of approximately $83.9 million as of June 30, 2026, supporting ongoing operations and development [S2].

Harrow's late-stage pipeline, particularly MELT-300, represents a potential transformative non-opioid sedation therapy with applications beyond ophthalmology, which could broaden its market reach. The company's expanding branded portfolio, including biosimilars and novel ophthalmic drugs, leverages its commercial infrastructure. Its compounding business provides a diversified revenue stream and access to customized therapies. Strong liquidity and operational scale in compounding facilities support growth initiatives [S1][S2].

Harrow faces significant pricing and reimbursement pressures from government and commercial payors that may limit revenue growth and profitability. The company reported net losses and negative earnings per share in recent quarters. Dependence on third-party manufacturers introduces supply chain risks. Competition from larger pharmaceutical companies and alternative therapies may constrain market share. Regulatory and clinical development risks remain for pipeline products, including timing and approval uncertainties [S1][S2].

Harrow's moat is supported by its comprehensive portfolio of FDA-approved ophthalmic products addressing multiple disease states, including proprietary formulations and biosimilars. Its established relationships with over 10,000 U.S. eyecare prescribers and institutions, combined with its compounding capabilities and late-stage pipeline assets like MELT-300, provide competitive differentiation. However, the company faces competition from larger pharmaceutical firms with greater resources and from alternative therapies, including generics and biosimilars. Regulatory and reimbursement challenges also impact market access and pricing power [S1].

• Pricing and Reimbursement Pressure: Sales depend on coverage and reimbursement from government and commercial payors, with ongoing measures to manage utilization and contain costs potentially reducing patient access and limiting pricing flexibility [S2].
• Clinical and Regulatory Risks: Pipeline products such as MELT-300 require successful completion of regulatory submissions and approvals; delays or negative outcomes could impact commercialization plans [S1].
• Competition: The company competes with larger pharmaceutical firms with greater resources and a range of branded, generic, and biosimilar ophthalmic therapies [S1].
• Supply Chain Dependence: Harrow relies on third-party manufacturers for its branded products, which may pose risks related to production capacity, quality, and geographic concentration [S1].
• Financial Performance: Recent quarters show net losses and negative earnings per share, indicating ongoing challenges in achieving profitability [S2].

• Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, focusing on safe, effective, accessible, and affordable medications to improve patient compliance and clinical outcomes [S1].
• The company markets a comprehensive portfolio of FDA-approved ophthalmic products addressing conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface and retina diseases [S1].
• Harrow owns U.S. commercial rights to multiple branded ophthalmic products including IHEEZO, VEVYE, TRIESENCE, BYOOVIZ (a LUCENTIS biosimilar), OPUVIZ (an EYLEA biosimilar), BYQLOVI, VIGAMOX, ILEVRO, FLAREX, NATACYN, TOBRADEX ST, ZERVIATE, VERKAZIA, NEVANAC, FRESHKOTE, MAXITROL, MAXIDEX, and IOPIDINE [S1].
• The company has out-licensed Canadian rights for several products to Apotex Inc. and owns worldwide rights to NATACYN and FRESHKOTE [S1].
• Harrow's development pipeline focuses on differentiated pharmaceutical therapies for eye care and adjacent markets, weighted toward late-stage and near-commercial assets [S1].
• Key pipeline programs include MELT-300 (a patented sublingual tablet combining midazolam and ketamine for sedation), H-N08 (triamcinolone acetonide ophthalmic program), CR-01 (conjunctival delivery device), and MELT-210 (midazolam ODT) [S1].
• MELT-300 completed Phase 3 clinical trials with FDA Special Protocol Assessment and is advancing toward NDA submission, with ongoing non-clinical and pharmacokinetic studies [S1].
• Harrow acquired the remaining equity interests of Melt Pharmaceuticals in November 2025, consolidating ownership of MELT-300 and related R&D activities [S1].
• The company operates two compounding facilities in New Jersey (one FDA-registered 503B outsourcing facility and one licensed 503A pharmacy) producing over 30 compounded ophthalmic formulations [S1].
• Harrow does not manufacture its branded pharmaceutical products but relies on third-party manufacturers located in various countries including the U.S., France, Belgium, Spain, and Taiwan [S1].
• Sales and marketing efforts are primarily focused in the U.S., targeting eyecare professionals, ambulatory surgery centers, healthcare systems, and hospitals [S1].
• The company reported a net loss of $17.27 million for the quarter ended June 30, 2026, with basic and diluted EPS of -$0.46, and cash and equivalents of approximately $83.9 million as of that date [S2].
• Current assets were $229.3 million and current liabilities $102.2 million as of June 30, 2026, resulting in a current ratio of 2.24 and a cash ratio of 0.89 [S2].
• Harrow's revenues for the quarter ended June 30, 2026, were not disclosed in recent filings; the latest available revenue figure is $10.38 million from 2018 [S2].
• The company faces pricing and reimbursement pressures from government and commercial third-party payors, including Medicare and private insurers, which may affect profitability and patient access [S2].
• Recent news includes Q1 2026 earnings reporting a loss and revenue below expectations, with detailed earnings call transcripts and highlights available [N2][N3][N4].
• Harrow is advancing clinical development and commercialization of MELT-300 as a non-opioid, non-IV sublingual sedation therapy with potential applications beyond ophthalmology [S1].
• The company has recently launched or plans to launch several biosimilars and novel ophthalmic products in mid-2026 and beyond [S1].